scarring Frontal Fibrosing Alopecia GWAS Implicates Risk Loci with Links to Immune System Together with gene expression results from affected tissue, the findings suggest that drugs such as JAK inhibitors may be effective for the treatment of FFA. OliX Receives Government Grant to Develop Anti-scarring Drug Premium The drug is designed to silence connective tissue growth factor, which is implicated in scarring and fibrosis. RXi Inks Deal to Sell Anti-scarring Drug in EU Prior to Approval Premium RXi Pharmaceuticals said this week that it has signed a deal giving the European Union distribution rights to its investigational anti-scarring drug RXI-109 to UK-based Ethicor. RXi Begins Phase II Trial of Anti-scarring Drug, Posts Q3 Results Premium This article has been updated to include details about RXi's third quarter financial results. RXi Pharmaceuticals this week announced that it has begun dosing patients in a phase II trial of its investigational anti-scarring drug RXI-109. RXi Releases Phase I Data on Anti-Scarring Drug, Aims for Phase II This Year Premium RXi Pharmaceuticals this week released data from a phase I trial of its dermal anti-scarring drug RXI-109, showing that the compound was safe and well-tolerated. Jun 6, 2013 Phase I Data Shows RXi Anti-Scarring Drug Safe, Well-tolerated Premium Apr 4, 2013 Following Private Placement, RXi Has Funds to Last into 2015 Premium Feb 21, 2013 RXi Releases Blinded Phase I Data Hinting at Efficacy of Anti-Scarring Drug, On Track for Phase II Premium Dec 6, 2012 RXi Begins Second Phase I Trial of Anti-Scarring Drug Premium Nov 15, 2012 RXi Releases Positive Safety Data on Scarring Drug, Posts Higher Q3 Loss on Dividend Premium Sep 27, 2012 RXi Completes Enrollment in Phase I Anti-Scarring Drug Trial Premium Jun 28, 2012 RXi Begins Phase I Trial of Anti-Scarring Drug Candidate Premium May 31, 2012 RXi Cleared to Begin Phase I Testing of Anti-Scarring Drug Premium May 10, 2012 RXi Gets Spun Out of Galena, Names New CEO as it Loses Its CSO Premium Feb 9, 2012 BioMolecular Therapeutics Inks Deal with Samyang, Aims for Korean IND in '13 Premium Apr 21, 2011 RXi Looks to Raise $10.9M in Public Offering; Needs More than $2M to Move Cancer Rx into Phase III Premium Feb 3, 2011 RXi Aims for First Clinical Trial in 2012 Premium Jun 17, 2010 RXi Says Initial Rx Focus Will Be Anti-Scarring, Retinal Disorders Premium Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.